Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) Findings support the therapeutic potential of ZYMFENTRA in addressing persistent treatment gaps especially in ileum-dominant CD INCHEON, South Korea, Nov. 26, 2025 /PRNewswire/ -- Celltrion, Inc....
Vital Signs highlights how researchers are “cracking the code on the genome” to harness the biomedical superpowers of hibernating animals
HONG KONG, Nov. 26, 2025 /PRNewswire/ -- In a groundbreaking new episode, CNN's long-running series Vital Signs delves into the cutting-edge science of hibernation, revealing how the secrets of the animal kingdom could unlock revolutionary advancements in human health, from fighting cancer and heart disease to facilitating space travel. This November, CNN's Chief...
Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy
– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 36, which was the study's primary endpoint, was -58.54%. Sparsentan was well-tolerated with a profile consistent with other global trials and no new safety...
Korea Innovation Foundation selects 2 Innovative bio health companies, LEEBIO, and Airlab for Global Technology Commercialization Support Program (North America)
DAEJEON, South Korea, Nov. 26, 2025 /PRNewswire/ -- Korea Innovation Foundation (INNOPOLIS), currently operating the 2025 Global Technology Commercialization Support Program (North America), announces that 2 innovative companies, LEEBIO, and Airlab are chosen for the support program. This initiative selects innovative technology companies in the fields of machinery, energy, AI/IoT and bio health. The program provides comprehensive consulting support...
Chiron Medical Advances Women’s Health with Expanded “1:1 Breast Health Empowerment Charity Campaign”
300 Free 3D Mammogram Screenings Donated to Community Women, Championing Self-Care and Compassionate Support HONG KONG, Nov. 26, 2025 /PRNewswire/ -- Building on its commitment to accessible healthcare, Chiron Medical Group (Referred as "Chiron") launched the "1:1 Breast Health Empowerment Charity Campaign" earlier this year, delivering 105 free 3D mammogram screenings and personalized medical consultations to underprivileged women. Through...
The Unseen Itch: Over Half of Singaporeans With Eczema Struggle With Sleep Loss, Shame and Social Withdrawal Due to Itch
A recently concluded survey by Medical Channel Asia sheds light on the debilitating effects of constant itch caused by eczema. SINGAPORE, Nov. 25, 2025 /PRNewswire/ -- A new ground-up survey "The Unseen Itch: How Eczema Disrupts Daily Life in Singapore" by Medical Channel Asia has uncovered a stark and often overlooked reality about itch. For people living with atopic dermatitis,...
Precious Hospital Sdn. Bhd. to Launch Cancer Centre and Hospital in Johor Bahru
First cyclotron outside Klang Valley to anchor Malaysia's advanced cancer care ecosystem KEY-HIGHLIGTHS RM500 million investment in advanced cancer care infrastructure State-of-the-art diagnostic and treatment facilities, including a nuclear medicine centre First cyclotron outside the Klang Valley enabling local radioisotope production for cancer detection and therapy Located in Larkin Sentral within the Johor–Singapore Special Economic Zone (JS-SEZ)...
Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America
SINGAPORE, Nov. 26, 2025 /PRNewswire/ -- Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialization, for the commercialization of Tuznue® (trastuzumab) across Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay. Tuznue® is...
Professor Chan Heum Park’s Team at Hallym University Chuncheon Sacred Heart Hospital Sends Their Self-Developed “BioCabinet” to Space Aboard Nuri Rocket
SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- Chan Hum Park, M.D., Ph.D., Professor of Otolaryngology at Hallym University Chuncheon Sacred Heart Hospital and Director of the Nano-Bio Regenerative Medical Institute at Hallym University, leads the research team whose space biology payload, BioCabinet, will launch aboard the Nuri rocket's fourth flight on November 27, as part of the mission carrying...
Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is expressed in most solid and hematological cancers. IVT-8086 is the only cancer therapeutic that targets multiple cell types associated with cancer including the tumor, and multiple components of the tumor microenvironment including...
